In the News
Groundbreaking research involving artificial intelligence could diagnose ALS patients sooner
Five thousand people in the U.S. are diagnosed with a neurological disease called ALS every year. Medical experts say it typically takes an average of two years to diagnose, but new research will likely make that timetable a lot shorter.
NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study
EverythingALS, a patient-focused non-profit that brings together patients, caregivers, physicians, researchers, and pharmaceutical companies using technological innovations and
‘Death by 1,000 cuts:’ How emerging tech could change the journey for ALS patients
In 2016, Indu Navar’s husband, Peter Cohen, experienced the first symptom of what turned out to be amyotrophic lateral sclerosis (ALS), a progressive degenerative disease commonly known as Lou Gehrig’s disease.
These 2 Surprising Traits May Predict ALS, New Research Says
Amyotrophic lateral sclerosis (sometimes called Lou Gherig’s disease, or ALS) affects around 15,000 Americans, with about 5,000 receiving a new diagnosis each year, according to the Centers for Disease Control and Prevention
Live At 9: Researchers Collecting Audio and Video to Help ALS Detection
Remember the summer Americans took time to dump buckets of ice water on their heads to help fight the deadly disease ALS? This summer, there’s a more comfortable way to help researchers learn about ALS and other neurological disorders.
A Connecticut man is battling a fatal disease with ‘enormous courage’. Love and his work with an ALS group give him ‘purpose’
Three years ago Austen Eadie-Friedmann, 38, had a dynamic career in the pharmaceutical/biotech field working for a Fortune 500 company and living in exciting places such as New York City, Boston and Europe, with his husband, William DeGregorio.
Mitsubishi Tanabe Pharma joins EVERYTHINGALS consortium to help accelerate biomarker discovery for Neurological
February 28, 2022 (San Francisco, CA) -- Today, EverythingALS.org (EALS), a patient-centric, citizen-based California nonprofit accelerating the discovery of digital biomarkers for neurological diseases such as amyotrophic lateral sclerosis (ALS), announced that Mitsubishi Tanabe Pharma Holdings America, Inc.
ALS, Lou Gehrig’s Disease, takes many lives, Everything ALS is doing
Deb Fabricatore lost her younger brother to ALS in 2014, and became involved in ALS advocacy. Indu Navar lost her husband in 2019 and immediately stepped up into action by building a nonprofit devoted to honoring her husband.
Open-Data Platforms for Direct Engagement with Patients, Researchers, and Pharma
Indu Navar, CEO and Founder of EverythingALS, explores the roles of Artificial Intelligence, Machine Learning, and Brain Computer Interface in the search for a cure for ALS. She will also share innovative research studies on ALS detection, how Pharma can work with and support ALS patient advocates, and her key leadership lessons for digital health entrepreneurs and innovators.
Bay Area Nonprofit Seeks 300 Volunteers in ALS Speech Study
SAN FRANCISCO (CBS SF) -- A Bay Area nonprofit dedicated to advancing research on an incurable -- and fatal -- disease of the nervous system is looking for 300 more people by the end of this month to participate in the largest-ever research project on the illness.
EverythingALS Launches “Stories and Innovation in ALS” Podcast
October 21, 2021 (Silicon Valley, CA) – For an inside look at how ALS impacts patients and their caregivers as well as the innovations that researchers and clinicians are coming up with to find biomarkers, treatments, and cures for this life-threatening disease, start listening to the EverythingALS podcast,
Canada has been an early leader in the AI space and there is no shortage of activity flourishing across the country. Today, we welcome Fanny Sie from Roche Canada and Indu Navar of Everything ALS to talk about machine learning and the End ALS Kaggle Challenge.
New project to better identify and treat ALS uses AI and data sharing
I n health, science begins with the patient. Roche believes that the only way to improve the way Canadians access care is by working with all stakeholders, including public and private organizations, patient communities and citizens.
Richard Sperry, Head of Research Partnerships and Collaborations at EverythingALS
Richard Sperry, Head of Research Partnerships and Collaborations at EverythingALS, speaks about the use of biomarkers to better understand the progression of ALS. With the help of artificial intelligence, EverythingALS and their partners, Modality.ai, are tracking speech patterns to add to an expanding collection of ALS research.
EverythingALS Selected to Present at the American Academy of Neurology Annual Meeting, April 17-22
April 16, 2021 (Los Altos, CA) – EverythingALS, a California nonprofit dedicated to bringing technological innovations and data science to support people with ALS, has been selected to present its scientific research at the American Academy of Neurology (AAN)
Accelerating Rare Disease Research | Indu Navar | TEDxSantaCatalinaSchool
n this moving, personal talk, Indu Navar tells how she lost her husband, Peter Cohen, to ALS and what she is doing to bring together patients, families, researchers and people everywhere to change the way that rare diseases are looked at.
The Story of Modality.AI: HealthTech Award Winner
HealthTech Networking Club member and winner of the HealthTech Startup Award in January David Suendermann-Oeft, CEO and Founder of Modality.AI, spoke with the bene : studio team about what inspired him to start the company, their biggest achievements so far, and advice for startup leaders in the digital health space.
‘End ALS Challenge’ Invites AI Community to Tackle 3 Key Questions
Roche Canada’s Artificial Intelligence Centre of Excellence (AI CoE), in collaboration with Answer ALS and EverythingALS, opened a challenge that asks the global artificial intelligence (AI) community to model solutions for key questions in amyotrophic lateral sclerosis (ALS).
Roche Canada AI Centre to tackle ALS
MISSISSAUGA, Ont. – The Roche Canada Artificial Intelligence Centre of Excellence (AI CoE) is excited to collaborate with Answer ALS and EverythingALS to launch an initiative called the End ALS Challenge, with the support of ALS Society of Canada, Ontario Brain Institute (OBI) and NetraMark Corp.
Roche Canada Artificial Intelligence Centre of Excellence opens digital competition to tackle ALS
MISSISSAUGA, ON, March 18, 2021 /CNW/ - The Roche Canada Artificial Intelligence Centre of Excellence (AI CoE) is excited to collaborate with Answer ALS and EverythingALS to launch an initiative called the End ALS Challenge, with the support of ALS Society of Canada, Ontario Brain Institute (OBI) and NetraMark Corp